Biotechnology company Staten Biotechnology BV announced on Tuesday that it has started the dosing of its lead STT-5058 drug candidate in a first-in-human clinical study for the novel treatment for dyslipidaemia under a prior collaboration with Novo Nordisk.
The company added that STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk for the treatment of dyslipidaemia. This "recycling" antibody with extended half-life has the potential to lower triglyceride levels and increase clearance of ApoC3-containing atherogenic particles.
Under the terms of the agreement, Novo Nordisk is providing funding and support to Staten for the development of STT-5058 in this indication.The partners will able to rapidly progress from research to product manufacturing to a clinical trial for the lead drug candidate.
Multiple studies have identified ApoC3 levels to be inversely associated with a favourable lipid profile and insulin resistance, both key components in managing residual cardiovascular risk. Dyslipidemia is an abnormal amount of lipids triglycerides, cholesterol and/or fat phospholipids) in the blood, concluded the company.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal